Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on early morning-OFF (EMO) pattern. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor, was…Oral treatment of the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) with the neuro-inflammation inhibiting compound PRI-003
Objective: Demonstration of beneficial effects of neuro-inflammation inhibition for the treatment of amyotrophic lateral sclerosis (ALS). Background: Neuro-inflammation and immune-inflammatory processes are characteristics of the…A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes
Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations
Objective: To evaluate the potential added benefit of opicapone (OPC), compared with placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients…Identification and characterization of anti-prionic compounds that disassemble αSyn prions as a novel therapeutic approach for synucleinopathies
Objective: Stabilization of monomeric α-synuclein protein (αSyn) by transient and high-affinity binding ligands is a novel and highly innovative anti-prionic treatment strategy for synucleinopathies .…Identification and characterization of anti-prionic compounds that disassemble Tau prions as a novel therapeutic approach for tauopathies
Objective: Stabilization of monomeric Tau protein by transient and high-affinity binding ligands is a novel and highly innovative anti-prionic treatment strategy for tauopathies. Background: Tauopathies…Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes
Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…Refractory tremor: is perampanel a potentially useful therapy?
Objective: To describe our series of patients with refractory tremor eventually treated with perampanel and to analyse its clinical outcomes. Background: Up to 40% of…Influencing factors when living with Parkinson’s disease: beyond the disease symptomatology
Objective: To identify which are the factors that influence in the process of living with Parkinson's disease (PD). Background: Living with PD is a complex,…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 32
- Next Page »